Table 2

Baseline values of the 1223 patients with a known CCgR-status between 15 and 21 months

TotalLearning sampleValidation sample
1223 938 285 
Male sex 61% 61% 63% 
Median age, y (range) 52 (18-83) 52 (18-83) 52 (18-77) 
Median spleen size* (range) 1 (0-38) 1 (0-38) 0 (0-25) 
Baseline laboratory values 
    Platelets (× 109/L), median (range) 360 (34-3050) 366 (34-3020) 355 (113-3050) 
    % Blast cells, median (range) 1 (0-15) 1 (0-15) 1 (0-15) 
    % Eosinophils, median (range) 2 (0-20) 2 (0-20) 2 (0-14) 
    Leukocytes, × 109/L, median (range) 68 (1-571) 63 (2-571) 89 (2-520) 
    Hb, g/dl, median (range) 12 (2-18.2) 12 (5-18) 12 (6-18.2) 
    % Basophils, median (range) 3 (0-21) 3 (0-21) 4 (0-19) 
Treatment    
    Imatinib 400 mg/d 47% 52% 28% 
    Imatinib 400 mg/d combined with LDAC or IFNα 33% 29% 49% 
    Imatinib 600 or 800 mg/d 20% 19% 23% 
TotalLearning sampleValidation sample
1223 938 285 
Male sex 61% 61% 63% 
Median age, y (range) 52 (18-83) 52 (18-83) 52 (18-77) 
Median spleen size* (range) 1 (0-38) 1 (0-38) 0 (0-25) 
Baseline laboratory values 
    Platelets (× 109/L), median (range) 360 (34-3050) 366 (34-3020) 355 (113-3050) 
    % Blast cells, median (range) 1 (0-15) 1 (0-15) 1 (0-15) 
    % Eosinophils, median (range) 2 (0-20) 2 (0-20) 2 (0-14) 
    Leukocytes, × 109/L, median (range) 68 (1-571) 63 (2-571) 89 (2-520) 
    Hb, g/dl, median (range) 12 (2-18.2) 12 (5-18) 12 (6-18.2) 
    % Basophils, median (range) 3 (0-21) 3 (0-21) 4 (0-19) 
Treatment    
    Imatinib 400 mg/d 47% 52% 28% 
    Imatinib 400 mg/d combined with LDAC or IFNα 33% 29% 49% 
    Imatinib 600 or 800 mg/d 20% 19% 23% 

Learning sample comprised German, GIMEMA, and HOVON patients; validation sample comprised French and Nordic patients.12-16 

*

Reported as cm below the costal margin as assessed by palpation.

Close Modal

or Create an Account

Close Modal
Close Modal